Provita Sp. z o.o. — Clinical Trial Site

60 Registered trials

20 Currently recruiting

Organisation

Provita Sp. z o.o.

Location

Katowice, Poland

Identifier

ORG-100044037

Address

Ul. Fabryczna 15b, 40-611, Poland

Departments

#40795: Centrum Medyczne Angelius Provita
#40795:Centrum Medyczne Angelius Provita
2502 : Dermatology
40795: Centrum Medyczne Angelius Provita
5714: Allergology
Centrum Medyczne Angelius
Centrum Medyczne Angelius Provita
Centrum Medyczne Angelius Provita – Badania Kliniczne
Centrum Medyczne Angelius Provita ul. Fabryczna 13Dand 15B, 40-611Katowice
Centrum Medyczne Angelius Provita, Badania Kliniczne Angelius
Centrum Medyczne Angelius Provita( #1)
Dermatologia
Dermatology
Dermatology and Venerology
Dermatology Department
N/A
NA
not applicable/nie dotyczy
otolaryngology
POL03293: Dermatology
Provita Sp. z o.o.
Provita Sp. z o.o. , Centrum Medyczne Angelius Provita
reumathology

Clinical trials at this site (60)

Search interface

A Long-Term Extension Study to Evaluate the Safety and Efficacy of Ritlecitinib in Participants With Severe AA Who Have Completed Studies B7… Pending

2024-515439-31-00 Alopecia areata 5
A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate r… Pending

2025-524005-32-00 Rheumatoid arthritis 4
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
Dose-finding study of LAD603 in adults with alopecia areata Recruiting

2025-523342-27-00 Alopecia areata 4 2026-04-10
A Long-Term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older with Moderate to Severe Eczema Recruiting

2023-509124-18-00 Moderate-to-Severe Atopic Dermatitis 5 2025-12-19
Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Hidradenitis Suppurativa // Prurigo Nodularis // Vitili 5 2025-09-03
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-507039-39-00 Moderate to Severe Plaque Psoriasis 5 2024-03-22
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus E… Recruiting

2025-523552-31-00 Systemic Lupus Erythematosus 5 2026-05-07
A Phase 2 Study of Lesigercept (YH35324) in Adult Patients with Chronic Spontaneous Urticaria (CLEAR) Recruiting

2025-524006-14-00 Chronic Spontaneous Urticaria 4 2026-04-20
A Phase 2a double blind, randomized, parallel arm, placebo-controlled trial to investigate the effects of two dose levels of CIT-013 on dise… Recruiting

2025-521684-12-00 Hidradenitis Suppurativa 4 2026-01-13
A Phase 2 trial to investigate efficacy and safety of vipoglanstat in women with endometriosis Recruiting

2025-522452-16-00 Endometriosis related pain 4 2025-12-05
Platform study to evaluate the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis Recruiting

2024-519081-49-00 Moderate to severe atopic dermatitis 4 2025-10-28
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid… Recruiting

2025-520564-17-00 Hidradenitis suppurativa (HS) 5 2025-10-16
A study to determine the efficacy, safety, and tolerability of tibulizumab in adults with hidradenitis suppurativa Recruiting

2024-519736-17-00 Hidradenitis Suppurativa 4 2025-10-03
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age with Moderate-to-Severe Atopic Eczema Recruiting

2023-509121-51-00 Moderate-to-Severe Atopic Dermatitis 5 2025-09-30
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of PF-07275315 and PF-07264660 in Adult… Recruiting

2023-505218-68-00 Moderate-Severe Atopic Dermatitis 4 2025-06-12
Clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) and pla… Recruiting

2023-510338-10-00 Recurrent herpes labialis (RHL) 5 2025-01-15
This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting

2023-504713-76-00 Dermatitis atopic 5 2024-12-03
A study to learn if dapirolizumab pegol works and is safe in people with moderately to severely active systemic lupus erythematosus (SLE) Recruiting

2023-508191-11-00 Systemic lupus erythematosus (SLE) 5 2024-11-28
Long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus (OPUS OLE) Recruiting

2024-514354-67-00 Systemic lupus erythematosus 5 2024-11-01
A Phase 3 Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 Years of Age With Severe Alopecia Areata Ended

2024-515438-33-00 Alopecia areata 5 2026-01-12
A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis Ended

2025-522113-35-00 Atopic dermatitis 4 2026-01-07
Long-term safety and efficacy evaluation of lunsekimig in adult participants with chronic rhinosinusitis with nasal polyps (CRSwNP) who comp… Ended

2024-515912-27-00 Chronic rhinosinusitis with nasal polyps 4 2025-12-08